Investigational new drug company code: BGS649 + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obese Hypogonadotropic Hypogonadism
Conditions
Obese Hypogonadotropic Hypogonadism
Trial Timeline
Aug 1, 2010 → Aug 1, 2012
NCT ID
NCT01200862About Investigational new drug company code: BGS649 + Placebo
Investigational new drug company code: BGS649 + Placebo is a phase 2 stage product being developed by Novartis for Obese Hypogonadotropic Hypogonadism. The current trial status is terminated. This product is registered under clinical trial identifier NCT01200862. Target conditions include Obese Hypogonadotropic Hypogonadism.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01200862 | Phase 2 | Terminated |
Competing Products
9 competing products in Obese Hypogonadotropic Hypogonadism
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lorcaserin | Eisai | Phase 1 | 33 |
| Bardoxolone methyl + Placebo | Kyowa Kirin | Phase 1 | 33 |
| LIK066 + Placebo | Novartis | Phase 2 | 52 |
| Placebo + CT-388 | Roche | Phase 2 | 52 |
| Growth hormone treatment | Pfizer | Pre-clinical | 22 |
| BMS-963272 + Placebo | Bristol Myers Squibb | Phase 1 | 32 |
| ALN-4324 + Placebo | Alnylam Pharmaceuticals | Phase 1/2 | 38 |
| Aleniglipron + Placebo | Structure Therapeutics | Phase 2 | 47 |
| CRB-913 + Placebo | Corbus Pharmaceuticals | Phase 1 | 25 |